Tyra Biosciences Inc

NASDAQ TYRA

Data sourced from

and

Download Data

Tyra Biosciences Inc Accounts Payable Turnover Ratio 5 year CAGR for the year ending December 31, 2023

Tyra Biosciences Inc Accounts Payable Turnover Ratio 5 year CAGR is NA for the year ending December 31, 2023. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tyra Biosciences Inc Accounts Payable Turnover Ratio for the year ending December 31, 2022 was 0.00, a 0.00% change year over year.
Tyra Biosciences Inc Accounts Payable Turnover Ratio for the year ending December 31, 2021 was 0.00, a 0.00% change year over year.
Tyra Biosciences Inc Accounts Payable Turnover Ratio for the year ending December 31, 2020 was 0.00, a 0.00% change year over year.
Tyra Biosciences Inc Accounts Payable Turnover Ratio for the year ending December 31, 2019 was 0.00.

NASDAQ: TYRA

Tyra Biosciences Inc

CEO	Dr. Todd Harris Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	2656 State Street, Carlsbad, CA, United States, 92008
Employees	49
Sector	Healthcare
Industry	Biotechnology

Description

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Key trends